Captopril

Captopril is an ACE inhibitor used for the management of essential or renovascular hypertension, congestive heart failure, left ventricular dysfunction following myocardial infarction, and nephropathy. Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

Chemical structure of Captopril
Mechanism
Curator reviewed
Primary indication
For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics).Curator reviewed · 12 structured indications
Formula / weight
C9H15NO3S · 217.285 g/mol (avg)
First approval
Canada, 1996 · United States, 1981
Also known as
Captopryl · L-Captopril
Code names
C09AA01 · SA-333 · SQ-14225

Resolves to

Structure
InChIKeyFAKRSMQSSFJEIM-RQJHMYQMSA-NSMILESC[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

What you can answer from here — as of September 23, 2026

8Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,393Drug interactionsStructured to mechanism, not free text
Sign in
63Clinical trialsPhase, status and sponsor resolved per trial
Sign in
12Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
708Marketed productsAcross 10 countries and 171 labellers
Sign in
2ATC codesIncluding every combination product, plus 24 drug categories
Sign in
44+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Captopril, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account